<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00035893</url>
  </required_header>
  <id_info>
    <org_study_id>AMP 720</org_study_id>
    <nct_id>NCT00035893</nct_id>
  </id_info>
  <brief_title>The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART</brief_title>
  <official_title>The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemispherx Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemispherx Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, randomized, controlled study of the safety and efficacy
      including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic
      Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA &lt; 50 copies/ml (PCR)
      and CD4 levels &gt; 400.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAART-free time interval</measure>
    <time_frame>HAART adherence questionnaire completed weekly</time_frame>
    <description>To evaluate the potential effectiveness of Ampligen to increase the HAART-free time interval before HIV rebound during the STI of HAART.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Seropositivity</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Ampligen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Ampligen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Ampligen administered for first 64 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>poly I-poly C12U</intervention_name>
    <description>200-400 mg IV infusions 2x/week for 64 weeks</description>
    <arm_group_label>Ampligen</arm_group_label>
    <other_name>Ampligen</other_name>
    <other_name>Rintatolimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Adults at least 18 years of age.

          2. CD4 cell count of &gt; 400 cells.

          3. Plasma HIV-1 RNA &lt; 50 copies/ml on two occasions: one within the six weeks prior to
             starting Baseline and the other during Baseline.

          4. History of virologic success with suppression of HIV RNA level &lt; 50 copies/ml during
             the last nine months documented a minimum of two times during the last ten months or a
             minimum of three times during the last fifteen months while patient is receiving a
             HAART regiment. During the four months prior to starting Baseline, continuing through
             Baseline and the 64 week study period, the HAART regimen must remain unchanged and
             contain at least one of the following ten anti-retroviral drugs:

               -  Abacavir (Ziagen)

               -  Zidovudine (Retrovir) AZT

               -  Zalcitabine (Hivid) ddC

               -  Didanosine (Videx) ddl

               -  Stavudine (Zerit) d4T

               -  Efavirenz (Sustiva)

               -  Indinavir (Crixivan)

               -  Ritonavir (Norvir)

               -  Nelfinavir (Viracept)

               -  Amprenavir (Agenerase)

             Only one HIV plasma RNA level &gt; 50, but &lt; 100 copies/ml is permitted during the four
             month period immediately prior to starting Baseline.

          5. Karnofsky performance status of at least 70.

          6. The following laboratory parameters within 21 days prior to treatment:

               -  Hemoglobin &gt; 9.2 g/dL for men and &gt; 8.9 g/dL for women;

               -  Neutrophil count &gt; 1000;

               -  Platelet count &gt; 75,000;

               -  AST/ALT &lt; 4.0 x upper limit of normal (ULN);

               -  Serum creatinine &lt; 1.5 x ULN or a creatinine clearance &gt; 50 mL/min.

          7. Ability and willingness to give written informed consent.

          8. For females with child bearing potential: A negative serum pregnancy test within 14
             days prior to randomization. Females of child bearing potential agree to use an
             effective means of contraception.

          9. The patient must have completed any elective routine immunizations (including
             influenza vaccination) eight or more weeks prior to first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Strayer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hemispherx Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Center for Special Immunology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AltaMed Health Services Corporation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Circle Medical Center</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julia Torres, MD</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Trials</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Ubillos, MD</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christopher Lucasti, D.O.</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. Chris Woodward, DO</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2002</study_first_submitted>
  <study_first_submitted_qc>May 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2002</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment interruption</keyword>
  <keyword>HIV Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>poly(I).poly(c12,U)</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

